Oral Mucositis Clinical Trial
Official title:
An Exploratory, Randomised, Parallel Group Study, Comparing the Protective Effect of Soluble Beta-1,3/1,6-Glucan or Placebo in Oral Mucositis in Head and Neck Cancer Patients Receiving Radiation Therapy or Chemoradiotherapy
The purpose of this study is to explore the protective effect and safety of soluble
beta-1,3/1,6-glucan compared to placebo in oral mucositis in head and neck patients
receiving radiotherapy or chemoradiotherapy.
Hypothesis: Soluble beta-1,3/1,6-glucan will through its immunomodulating activities prevent
oral mucositis
Status | Completed |
Enrollment | 40 |
Est. completion date | July 2006 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients undergoing radiotherapy or chemoradiotherapy for histologically confirmed squamous cell carcinoma of oral cavity or oropharynx (1.8-2.0 Gy/day; 5 days per week, totally 59.4-70 Gy). - Normal mucosa at baseline (i.e. Common Toxicity Criteria (CTC) grade 0) - >= 18 years of age - Women of childbearing potential must use an adequate contraceptive method and have a negative pregnancy test - Written informed consent Exclusion Criteria: - Patients who will receive hyperfractionated or accelerated radiotherapy - History of malignancies within the past five years other than non-melanomatous skin cancers (with the exception of squamous cell carcinoma of the skin) or carcinoma in situ of the cervix - Previous neoplasm in the head and neck area, whether malignant or not - Previous radiation therapy for head and neck cancer - If wound from curative surgery have not healed - Patients expected to receive agents that would interfere with the investigator's ability to assess changes in the appearance of the mucositis during the study - Use of radiosensitizers - History or clinical evidence of active significant acute or chronic diseases that may compromise the ability to evaluate or interpret the effects of the study treatment on mucositis - Evidence of distant metastatic disease - Expected survival of less than 12 months - > grade 3 performance status (WHO grading) - Granulocyte count < 2.000/mm3 and platelet count < 100,000/mm3 - Serum creatinine >= 150 micromol/L - Total bilirubin >= 36 micromol/L, AST > 3 times the upper normal limit - Any subject who, in the opinion of the investigator, is unlikely to comply with the study procedures, or is unlikely to complete the study due to different reasons like e.g. language barriers or mental incapacity - Participation in a clinical trial in the last 30 days Receipt of any investigational product within 30 days prior to this trial |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Medical Centre Bonn, Clinic for Radiotherapy and Radiological Oncology | Bonn | |
Germany | Evangelisches Krankenhaus | Düsseldorf | |
United Kingdom | Royal Marsden Hospital, Head and Neck Unit | London |
Lead Sponsor | Collaborator |
---|---|
Biotec Pharmacon ASA |
Germany, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess actual grade of mucositis upon completion of radiotherapy or chemoradiotherapy and after prophylactic treatment with soluble beta-1,3/1,6-glucan or placebo. | |||
Secondary | To assess proportions of patients avoiding grade 2 or higher oral mucositis after treatment with soluble beta-1,3/1,6-glucan or placebo | |||
Secondary | To assess time before first sign of oral mucositis | |||
Secondary | To evaluate impact of toxicities like patients' pain and swallowing difficulty | |||
Secondary | To assess the safety of the investigational product |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02229136 -
Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
|
Phase 2 | |
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Enrolling by invitation |
NCT02662374 -
Oral Hygiene Regimen in Patients on HCT
|
Phase 4 | |
Completed |
NCT00938080 -
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
|
Phase 1 | |
Completed |
NCT00756951 -
Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT00701688 -
Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
Not yet recruiting |
NCT05059613 -
Thalidomide With or Without Probiotics in Radioactive Oral Mucositis
|
N/A | |
Completed |
NCT04440930 -
White Tea for Prevention of Chemotherapy Induced Mucositis
|
N/A | |
Completed |
NCT05705622 -
The Effect of Nursing Education on Oral Mucositis in Bone Marrow Transplant Patients
|
N/A | |
Completed |
NCT02399228 -
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis
|
Phase 2 | |
Withdrawn |
NCT02589860 -
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
|
||
Active, not recruiting |
NCT01772706 -
Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer
|
N/A | |
Enrolling by invitation |
NCT06122636 -
Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC
|
N/A | |
Completed |
NCT03689712 -
ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients
|
Phase 3 | |
Terminated |
NCT02539342 -
Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy
|
Phase 3 | |
Completed |
NCT02555501 -
Oral Mucositis and Laser Therapy Associated With Photodynamic Therapy
|
Phase 3 | |
Completed |
NCT01789658 -
Cryotherapy for Prevention of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT00790322 -
Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy
|
Phase 3 | |
Recruiting |
NCT00549952 -
Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients
|
N/A | |
Completed |
NCT05635929 -
Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients.
|
N/A |